{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:45:33Z","timestamp":1791233133235,"version":"4.1.0"},"reference-count":77,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chimeric antigen receptor\u2013engineered (CAR) T cells are emerging powerful therapies for patients with refractory\/relapsed B-cell lymphomas. [18F]FDG PET\/CT plays a key role during staging and response assessment in patients with lymphoma; however, the evidence about its utility in CAR-T therapies for lymphomas is limited. This review article aims to provide an overview of the role of PET\/CT during CAR-T cell therapy in B-cell lymphomas, focusing on the prognostic value of metabolic parameters, as well as on response assessment. Data from the literature report on the use of [18F]FDG PET\/CT at the baseline with two scans performed before treatment started focused on the time of decision (TD) PET\/CT and time of transfusion (TT) PET\/CT. Metabolic tumor burden is the most studied parameter associated with disease progression and overall survival, making us able to predict the occurrence of adverse effects. Instead, for post-therapy evaluation, 1 month (M1) PET\/CT seems the preferable time slot for response assessment and in this setting, the Deauville 5-point scale (DS), volumetric analyses, SUVmax, and its variation between different time points (\u2206SUVmax) have been evaluated, confirming the usefulness of M1 PET\/CT, especially in the case of pseudoprogression. Additionally, an emerging role of PET\/CT brain scans is reported for the evaluation of neurotoxicity related to CAR-T therapies. Overall, PET\/CT results to be an accurate method in all phases of CAR-T treatment, with particular interest in assessing treatment response. Moreover, PET parameters have been reported to be reliable predictors of outcome and severe toxicity.<\/jats:p>","DOI":"10.3390\/cancers14194700","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"4700","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy"],"prefix":"10.3390","volume":"14","author":[{"given":"Flavia","family":"Linguanti","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9370-102X","authenticated-orcid":false,"given":"Elisabetta Maria","family":"Abenavoli","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-6559","authenticated-orcid":false,"given":"Valentina","family":"Berti","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"Egesta","family":"Lopci","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, IRCCS\u2014Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk. Lymphoma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMx160005","article-title":"Chimeric Antigen Receptor\u2013Modified T Cells in Chronic Lymphoid Leukemia; Chimeric Antigen Receptor\u2013Modified T Cells for Acute Lymphoid Leukemia; Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"374","author":"Porter","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","unstructured":"(2022, March 29). U.S. Food & Drug Administration: YESCARTA (Axicabtagene Ciloleucel), Available online: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/uc.2017."},{"key":"ref_7","unstructured":"(2022, March 29). Axicabtagene Ciloleucel, Applications for New Human Medicines under Evaluation by the Committee for Medicinal Products for Human Use (EMA\/583158\/2017), 2017 September. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-002010-pip01-16-m02."},{"key":"ref_8","unstructured":"(2022, March 29). U.S. Food & Drug Administration: KYMRIAH (Tisagenlecleucel), Available online: https:\/\/www.fda.gov\/biologicsbloodvaccines\/cellulargenetherapyproducts\/approvedproducts\/ucm."},{"key":"ref_9","unstructured":"(2022, March 29). Tisagenlecleucel, Applications for New Human Medicines under Evaluation by the Committee for Medicinal Products for Human Use (EMA\/789956\/2017). December 2017. Available online: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/document_listing\/document_listing_000349.jsp&mid=WC0b01ac05805083eb."},{"key":"ref_10","unstructured":"(2021, October 25). U.S. Food and Drug Administration FDA Approves First Cell-Based Gene Therapy for Adult Patients with Relapsed or Refractory MCL, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cell-based-gene-therapy-adult-patients-relapsed-or-refractory-mcl."},{"key":"ref_11","unstructured":"(2021, December 11). European Medicines Agency TECARTUS (Brexucabtagene Autoleucel). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tecartus-epar-medicine-overview_en.pdf."},{"key":"ref_12","unstructured":"(2022, March 29). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/breyanzi."},{"key":"ref_13","unstructured":"(2022, March 29). Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell \u2028Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/02648725.2018.1430465","article-title":"CAR T-cells for cancer therapy","volume":"33","author":"Muhammad","year":"2017","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"djv439","DOI":"10.1093\/jnci\/djv439","article-title":"Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy","volume":"108","author":"Dai","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood-2011-03-344275","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00262-009-0704-9","article-title":"2B4 (CD244) signaling via chimeric receptors costimulates tumor-antigen specific proliferation and in vitro expansion of human T cells","volume":"58","author":"Altvater","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PPO.0000000000000034","article-title":"CD28z CARs and armored CARs","volume":"20","author":"Pegram","year":"2014","journal-title":"Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cpet.2019.08.011","article-title":"Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas","volume":"15","author":"Lopci","year":"2020","journal-title":"PET Clin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s11307-021-01627-8","article-title":"18F-Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography Following Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma","volume":"23","author":"Ruff","year":"2021","journal-title":"Mol. Imaging Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: An expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: Best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Chabannon","year":"2020","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13045-022-01256-w","article-title":"Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET\/CT","volume":"15","author":"Breen","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in difuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial","volume":"1","author":"Schmitz","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_34","first-page":"37","article-title":"SUVmax reduction improves early prognosis value of interim positron emission tomography scans in difuse large B-cell lymphoma","volume":"118","author":"Casasnovas","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Toledano, M.N., Vera, P., Tilly, H., Jardin, F., and Becker, S. (2019). Comparison of therapeutic evaluation criteria in FDG PET\/CT in patients with difuse large-cell B-cell lymphoma: Prognostic impact of tumor\/ liver ratio. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0211649"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1002\/cam4.2404","article-title":"Interim PET\/CT based on visual and semiquantitative analysis predicts survival in patients with difuse large B-cell lymphoma","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00259-018-4005-4","article-title":"Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?","volume":"45","author":"Cottereau","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jcyt.2018.10.003","article-title":"Early positron emission tomography\/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas","volume":"20","author":"Shah","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","article-title":"Tumor Burden Measured by 18F-FDG PET\/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma","volume":"11","author":"Hong","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","article-title":"Prognostic Impact of 18F-FDG PET\/CT in Patients with Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells","volume":"46","author":"Sesques","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12149-020-01544-w","article-title":"18F-FDG PET\/CT of of-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma","volume":"35","author":"Derlin","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00259-021-05551-5","article-title":"[18F]FDG PET\/CT in patients with DLBCL treated with CAR-T cell therapy: A practical approach of reporting pre- and post-treatment studies","volume":"49","author":"Cohen","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005807","article-title":"Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma","volume":"6","author":"Kuhnl","year":"2022","journal-title":"Blood Adv."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bailly, C., Carlier, T., Tessoulin, B., Gastinne, T., Kraeber-Bodere, F., Le Gouill, S., and Bodet-Milin, C. (2022). Prognostic value of FDG-PET\/CT response for patient selection before chimeric antigen receptor-T-cells therapy in non-Hodgkin lymphoma. Hematol. Oncol., 1\u20135.","DOI":"10.1002\/hon.2965"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"834288","DOI":"10.3389\/fonc.2022.834288","article-title":"Prognostic Value of Radiomic Features of 18F-FDG PET\/CT in Patients With B-Cell Lymphoma Treated with CD19\/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells","volume":"12","author":"Zhou","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Galtier, J., Vercellino, L., Chartier, L., Olivier, P., Tabouret-Viaud, C., Mesguich, C., Di Blasi, R., Durand, A., Raffy, L., and Gros, F.X. (Haematologica, 2022). PET-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T-cell, Haematologica, online ahead of print.","DOI":"10.3324\/haematol.2021.280550"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","article-title":"Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy","volume":"6","author":"Feng","year":"2022","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/j.bbmt.2019.06.036","article-title":"Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Byrne","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","article-title":"Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell","volume":"56","author":"Danyelesko","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1097\/RLU.0000000000003870","article-title":"Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma","volume":"47","author":"Boursier","year":"2022","journal-title":"Clin. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1007\/s00259-022-05722-y","article-title":"Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion","volume":"49","author":"Choen","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Eng. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd3801","article-title":"The determination and interpretation of the therapeutic index in drug development","volume":"11","author":"Muller","year":"2012","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the Beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10428194.2011.622420","article-title":"Glucose metabolism correlated with cellular proliferation in diffuse large B-cell lymphoma","volume":"53","author":"Wu","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood. Marrow Transpl."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00415-020-10237-3","article-title":"Neurological updates: Neurological complications of CAR-T therapy","volume":"268","author":"Tallantyre","year":"2021","journal-title":"J. Neurol."},{"key":"ref_72","first-page":"178","article-title":"Brain 18F-FDG PET\/CT: Utility in the Diagnosis of Dementia and Epilepsy","volume":"22","author":"Lotan","year":"2022","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00259-018-4035-y","article-title":"Clinical Utility of FDG PET\/CT for the differential diagnosis among the mail forms of dementia","volume":"45","author":"Nestor","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Daniel","year":"2019","journal-title":"Brain"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1007\/s00259-021-05562-2","article-title":"[18F]FDG PET\/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a difuse large B cell lymphoma patient with ICANS","volume":"49","author":"Paccagnella","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neurol.2021.01.019","article-title":"Hypometabolism on brain FDG PET\/CT as a marker for neurotoxicity after CAR T-cell therapy: A case report","volume":"178","author":"Vernier","year":"2022","journal-title":"Rev. Neurol."},{"key":"ref_77","unstructured":"ACR Guidelines and Standards Committee (2022, March 29). ACR-SPR Practice Parameter for Performing FDG-PET\/CT in Oncology. American College of Radiology; 2014. Available online: http:\/\/www.acr.org\/~\/media\/71B746780F934F6D8A1BA5CCA5167EDB.pdf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4700\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:40:38Z","timestamp":1760143238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":77,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194700"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194700","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}